EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische Studie

First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 study

Hisateru Yasui, Masaki Aizawa, Kensei Yamaguchi, Akihito Kawazoe, Hiroki Hara, Masahiro Tsuda, Hirokazu Shoji, Naotoshi Sugimoto, Nobuhiro Shibata, Kenji Amagai, Yasuhiro Choda, Shiro Iwagami und 6 weitere

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-025-02847-6 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Hisateru Yasui und 17 weiteren Autor:innen. Beteiligte Einrichtung: Kobe City Medical Center General Hospital, Kobe, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Stomach Neoplasms, Esophagogastric Junction, Adenocarcinoma. Die Arbeit nennt 15 Literaturangaben. Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In the global phase 3 KEYNOTE-859 study (NCT03675737), first-line pembrolizumab plus chemotherapy significantly improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) versus placebo plus chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This post hoc analysis of KEYNOTE-859 evaluated outcomes in participants enrolled in Japan. METHODS: Participants with untreated locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma were randomly assigned to receive pembrolizumab 200 mg or placebo intravenously every 3 weeks for ≤ 35 cycles plus investigator's choice of chemotherapy. The primary end point was OS. Secondary end points were ORR, DOR, and PFS per RECIST v1.1, by blinded independent central review, and safety. Data cutoff was October 3, 2022. RESULTS: Overall, 101 participants were enrolled in Japan (n = 48 pembrolizumab plus chemotherapy [pembrolizumab group]; n = 53 placebo plus chemotherapy [placebo group]). Median follow-up was 28.9 months (range, 22.0-42.0). Median OS was 16.8 months with pembrolizumab versus 13.3 months with placebo (hazard ratio [HR], 0.71; 95% CI, 0.44-1.13). Grade 3 or 4 treatment-related adverse events occurred in 41.7% of participants given pembrolizumab and 39.6% of participants given placebo; none were grade 5. CONCLUSIONS: Consistent with the global KEYNOTE-859 results, OS was better with pembrolizumab plus chemotherapy, with manageable safety, for participants enrolled in Japan. Results continue to support pembrolizumab plus chemotherapy as a new first-line treatment option for patients with advanced or metastatic HER2-negative gastric or GEJ adenocarcinoma. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03675737.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedStomach NeoplasmsEsophagogastric JunctionAdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsHumansFemaleMaleMiddle AgedAgedJapanAdultAged, 80 and overProgression-Free Survival

Stichwörter der Autor:innen

AdenocarcinomaGastric cancerGastroesophageal junction cancerJapanPembrolizumab

Substanzen

Antibodies, Monoclonal, Humanizedpembrolizumab

Autor:innen und Institutionen

  • Kobe City Medical Center General Hospital, Kobe, Japan.
  • Niigata Cancer Center Hospital, Niigata, Japan.
  • The Cancer Institute Hospital of Japanese Foundation for Cancer, Tokyo, Japan.
  • National Cancer Center Hospital East, Kashiwa, Japan.
  • Saitama Cancer Center, Saitama, Japan.
  • Hyogo Cancer Center, Akashi, Japan.

Förderung

  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Zitieren

APA

Yasui, H., Aizawa, M., Yamaguchi, K., Kawazoe, A., Hara, H., Tsuda, M., Shoji, H., Sugimoto, N., Shibata, N., Amagai, K., Choda, Y., Iwagami, S., Esaki, T., Kadowaki, S., Shiratori, S., Han, S., Bordia, S., & Shitara, K. (2025). First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 study. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02847-6

Vancouver

Yasui H, Aizawa M, Yamaguchi K, Kawazoe A, Hara H, Tsuda M, et al. First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 study. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02847-6

BibTeX
@article{Yasui2025,
  author = {Yasui, Hisateru and Aizawa, Masaki and Yamaguchi, Kensei and Kawazoe, Akihito and Hara, Hiroki and Tsuda, Masahiro and Shoji, Hirokazu and Sugimoto, Naotoshi and Shibata, Nobuhiro and Amagai, Kenji and Choda, Yasuhiro and Iwagami, Shiro and Esaki, Taito and Kadowaki, Shigenori and Shiratori, Shinichi and Han, Shirong and Bordia, Sonal and Shitara, Kohei},
  title = {First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 study},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-025-02847-6}
}
Kostenlos starten →